Alexion to Acquire Wilson Therapeutics: Click Here For Transaction Details and Disclosures
Share, Send, or Save

Pipeline

Alexion is advancing a rare disease pipeline that builds on our fundamental strength in complement biology and focuses on our core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. We are steadfast in our pursuit of groundbreaking innovation, and aim to redefine what it means to live with a rare disease.

Full Pipeline

Market
Advanced Clinical Development
Early Clinical
Development
Preclinical
Filter by:
 
 
Generate PDF
 

Soliris® (eculizumab) for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase: Market

 
 

Soliris® (eculizumab) for Atypical Hemolytic Uremic Syndrome (aHUS)
Phase: Market

 
 

Soliris® (eculizumab) for Anti-AchR+ Generalized Myasthenia Gravis (gMG)
Phase: Market

 
 

Strensiq® (asfotase alfa) for Hypophosphatasia (HPP)
Phase: Market

 
 

Kanuma® (sebelipase alfa) for Lysosomal Acid Lipase Deficiency (LAL-D)
Phase: Market

 
 

Soliris® (eculizumab) for Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase: Advanced Clinical Development

 
 

ALXN1210 IV for PNH
Phase: Advanced Clinical Development

 
 

ALXN1210 IV for aHUS
Phase: Advanced Clinical Development

 
 

WTX101 for Wilson Disease
Phase: Advanced Clinical Development

 
 

ALXN1210 Subcutaneous QW
Phase: Early Clinical Development

 
 

ALXN1210 IV for Generalized Myasthenia Gravis (gMG)
Phase: Early Clinical Development

 
 

ALXN1210 IV for IgA Nephropathy (IgAN)
Phase: Preclinical

 
 

ALXN1210 Next-Generation Subcutaneous Q2W or Q4W
Phase: Preclinical

 
 

CP010
Phase: Preclinical

 
 

Additional Complement
Phase: Preclinical